查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446992

到 2030 年急性細菌性皮膚和皮膚結構感染市場預測 - 依感染類型、診斷類型、治療、給藥途徑、配銷通路和地理位置的全球分析

Acute Bacterial Skin & Skin Structure Infection Market Forecasts to 2030 - Global Analysis By Infection Type, Diagnostic Type, Treatment, Route of Administration, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球急性細菌性皮膚和皮膚結構感染市場規模為 117.0832 億美元，預計到 2030 年將達到 252.431 億美元，預測期內CAGR為 11.6%。急性細菌性皮膚和皮膚結構感染 (ABSSSI) 是指影響皮膚和皮下組織的一系列細菌感染，通常由金黃色葡萄球菌和化膿性鏈球菌引起。這些感染表現為感染部位發紅、發熱、腫脹和疼痛等症狀。 ABSSSI 的範圍可以從輕微的蜂窩性組織炎到更嚴重的情況，如膿腫或傷口感染。及時診斷和治療對於預防 ABSSSI 病例的併發症和促進癒合至關重要。

根據 2022 年 8 月發表在《國際抗菌藥物雜誌》上的一項研究，美國近 10% 的入院病例和歐洲醫院治療的所有感染中約 15% 是由 ABSSSI 引起的。

市場動態：

驅動因素：

增加醫療保健支出

不斷成長的醫療保健支出促進了旨在為 ABSSSI 開發創新療法和診斷工具的研究和開發工作。隨著醫療保健預算的增加，醫療保健系統有能力實施先進的診斷技術，例如分子檢測和即時檢測。此外，支出的增加使得針對抗生素抗藥性細菌的新療法的開發和採用成為可能，這進一步推動了該市場的發展。

阻礙因素：

醫療基礎設施不足

有限的醫療設施和資源可能導致醫院和診所過度擁擠，進一步加劇醫療保健系統的壓力並降低優質護理的提供。如果沒有適當的傷口護理、無菌操作和抗生素管理設施，管理 ABSSSI 病例將變得更具課題性，並可能增加併發症和治療失敗的風險。此外，醫療基礎設施不足可能會進一步阻礙這個市場。

機會：

診斷學的進步

技術創新徹底改變了傳染病診斷領域，能夠更快、更準確、更有效率地識別致病病原體。這些診斷技術的進步不僅可以透過早期準確診斷 ABSSSI 來改善患者的治療效果，還可以透過最佳化抗生素的使用和降低抗生素抗藥性的風險來促進抗菌藥物管理工作，從而逐漸推動這一市場的成長。

威脅：

認知和診斷有限

醫療保健提供者和患者對 ABSSSI 症狀、危險因素和適當的管理策略缺乏認知，導致尋求醫療護理的延誤、誤診或抗生素的不當使​​用。此外，醫療保健提供者對 ABSSSI 的認知有限可能會導致診斷錯誤；因此，患者可能會出現併發症、疾病進展和醫療費用增加，阻礙該市場的擴張。

Covid-19 影響

COVID-19 大流行對急性細菌性皮膚和皮膚結構感染（ABSSSI）市場產生了一些負面影響。在大流行期間，醫療保健資源被轉移到管理 COVID-19 患者上，導致非緊急手術、擇期手術和常規就診的延誤。此外，大流行的經濟影響，包括失業、醫療保健預算減少和供應鏈中斷，對患者和醫療保健系統造成了財務限制，從而阻礙了這個市場。

在預測期內，醫院獲得的部分預計將是最大的

據估計，醫院獲得的部分佔據最大佔有率。它是指患者在住院或前往醫療機構就診期間所獲得的感染。與社區獲得性感染相比，醫院獲得性 ABSSSI 通常涉及更廣泛的細菌。此外，醫療保健提供者必須仔細考慮抗生素的選擇，並可能採用廣譜藥物或聯合療法來有效治療這些感染，從而顯著促進該區隔市場的擴張。

革蘭氏染色領域預計在預測期內CAGR最高

革蘭氏染色部分預計在預測期內具有最高的CAGR，因為它是一種用於根據細胞壁組成對細菌進行分類的診斷技術。革蘭氏染色涉及使用結晶紫和碘，將細菌分為兩大類：革蘭氏陽性菌和革蘭氏陰性菌。此外，革蘭氏染色技術的進步，例如快速自動化系統和即時檢測設備，正在推動該領域的成長。

佔比最大的地區：

由於醫療保健環境多樣化以及各國感染流行模式不同，亞太地區在推斷期內佔據了最大的市場佔有率。該地區強大的醫療基礎設施和對實證醫學的重視推動了對 ABSSSI 創新治療和診斷解決方案的需求。此外，利害關係人之間的合作推動創新、臨床研究和先進診斷技術的採用，從而推動該地區的擴張。

複合CAGR最高的地區：

由於歐洲更加重視提高診斷能力、加強感染預防措施以及開發新療法來應對不斷上升的 ABSSSI 發病率，預計歐洲在預測期內將出現最高的CAGR。該地區是一些主要參與者的所在地，例如Melinta Therapeutics, Inc.、Melinta Therapeutics, Inc. 和輝瑞公司(Pfizer, Inc.)。因此，它為公司提供了重要的機會來創新、擴大產品範圍、為改善患者狀況做出貢獻成果，並推動該地區的成長。

主要進展：

2024 年 1 月，Glenmark Pharmaceuticals Ltd. 宣布成立聯盟 - Ichnos Glenmark Innovation - 以加速癌症治療新藥的發現。

2023 年 12 月，輝瑞公司公佈了 2b 期臨床試驗的主要資料，該試驗調查其口服胰高血糖素樣肽 1 受體激動劑候選藥物 danuglipron，用於治療肥胖且無 2 型糖尿病的成年人。

2023 年 9 月，Glenmark Pharmaceuticals Limited 與 Nirma Limited 簽訂最終協議，以總代價剝離其子公司 Glenmark Life Sciences Limited（「GLS」）75% 的股權，但須視成交調整而定。

我們的報告提供了什麼：

  • 區域和國家層面的市場佔有率評估
  • 對新進入者的策略建議
  • 涵蓋2021年、2022年、2023年、2026年及2030年的市場資料
  • 市場趨勢（促進因素、限制因素、機會、威脅、課題、投資機會和建議）
  • 根據市場預測提出關鍵業務部門的策略建議
  • 競爭性景觀美化繪製主要共同趨勢
  • 公司概況，包括詳細的策略、財務狀況和最新發展
  • 反映最新技術進步的供應鏈趨勢

免費客製化產品：

本報告的所有客戶都將有權獲得以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 個）
    • 關鍵參與者的 SWOT 分析（最多 3 個）
  • 區域區隔
    • 根據客戶的興趣對任何主要國家的市場估計、預測和CAGR（註：取決於可行性檢查）
  • 競爭基準化分析
    • 根據產品組合、地理分佈和策略聯盟對主要參與者基準化分析

目錄

第 1 章：執行摘要

第 2 章：前言

  • 抽象的
  • 股東
  • 研究範圍
  • 研究方法論
    • 資料探勘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 研究來源
    • 主要研究來源
    • 二手研究來源
    • 假設

第 3 章：市場趨勢分析

  • 介紹
  • 促進要素
  • 限制
  • 機會
  • 威脅
  • 新興市場
  • Covid-19 的影響

第 4 章：波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭競爭

第 5 章：全球急性細菌性皮膚和皮膚結構感染市場：依感染類型

  • 介紹
  • 社區獲得性
  • 醫院獲得性
  • 其他感染類型

第 6 章：全球急性細菌性皮膚和皮膚結構感染市場：依診斷類型

  • 介紹
  • 臨床診斷
  • 革蘭氏染色
  • 血液檢查
  • 生物標記檢測
  • 分子診斷
  • 微生物培養
  • 其他診斷類型

第 7 章：全球急性細菌性皮膚和皮膚結構感染市場：依治療方法

  • 介紹
  • 特地唑胺
  • 德拉沙星
  • 達托黴素
  • 萬古黴素
  • 替加環素
  • 頭孢洛林酯
  • 利奈唑胺
  • 奧利萬星
  • 其他治療

第 8 章：全球急性細菌性皮膚和皮膚結構感染市場：依給藥途徑

  • 介紹
  • 注射用
  • 專題
  • 口服

第 9 章：全球急性細菌性皮膚和皮膚結構感染市場：依配銷通路

  • 介紹
  • 零售藥局
  • 醫院藥房
  • 網路藥局
  • 其他分銷管道

第 10 章：全球急性細菌性皮膚和皮膚結構感染市場：依地理位置

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第 11 章：主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 擴充
  • 其他關鍵策略

第 12 章：公司概況

  • Paratek Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Cumberland Pharmaceuticals Inc.
  • Allergan
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Melinta Therapeutics, Inc.
  • Glenmark Pharmaceuticals Ltd
  • Endo Pharmaceuticals Inc.
  • Nabriva Therapeutics PLC
  • Basilea Pharmaceutica Ltd
  • Cipher Pharmaceuticals
  • Menarini Group
  • Sandoz Inc.
Product Code: SMRC25253

According to Stratistics MRC, the Global Acute Bacterial Skin & Skin Structure Infection Market is accounted for $11,708.32 million in 2023 and is expected to reach $25,243.1 million by 2030 growing at a CAGR of 11.6% during the forecast period. Acute Bacterial Skin and Skin Structure Infection (ABSSSI) refers to a range of bacterial infections affecting the skin and underlying tissues, commonly caused by Staphylococcus aureus and Streptococcus pyogenes. These infections manifest with symptoms like redness, warmth, swelling, and pain at the site of infection. ABSSSIs can range from mild cellulitis to more severe conditions like abscesses or wound infections. Prompt diagnosis and treatment are crucial to prevent complications and promote healing in ABSSSI cases.

According to a study published in the International Journal of Antimicrobial Agents in August 2022, almost 10% of all hospital admissions in the United States and around 15% of all infections treated in European hospitals are due to ABSSSIs.

Market Dynamics:

Driver:

Increasing healthcare expenditure

Rising healthcare expenditures foster research and development efforts aimed at developing innovative therapies and diagnostic tools for ABSSSI. With higher healthcare budgets, healthcare systems can afford to implement advanced diagnostic techniques, such as molecular testing and point-of-care testing. Additionally, increased expenditure allows for the development and adoption of novel therapies targeting antibiotic-resistant bacteria, which is propelling this market further.

Restraint:

Inadequate healthcare infrastructure

Limited healthcare facilities and resources can lead to overcrowding in hospitals and clinics, further exacerbating the strain on the healthcare system and decreasing the delivery of quality care. Without proper facilities for wound care, sterile procedures, and antibiotic administration, managing ABSSSI cases becomes more challenging and may increase the risk of complications and treatment failures. Moreover, inadequate healthcare infrastructure can hinder this market further.

Opportunity:

Advancements in diagnostics

Technological innovations have revolutionized the field of infectious disease diagnosis, enabling faster, more accurate, and more efficient identification of causative pathogens. These advancements in diagnostics not only improve patient outcomes by enabling early and accurate diagnosis of ABSSSI but also contribute to antimicrobial stewardship efforts by optimizing antibiotic use and reducing the risk of antibiotic resistance, which gradually boosts this market growth.

Threat:

Limited awareness and diagnosis

A lack of awareness among both healthcare providers and patients about ABSSSI symptoms, risk factors, and appropriate management strategies leads to delays in seeking medical care, misdiagnosis, or inappropriate use of antibiotics. Moreover, limited awareness of ABSSSI among healthcare providers may contribute to diagnostic errors; as a consequence, patients may experience complications, disease progression, and increased healthcare costs, thereby hampering this market expansion.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the Acute Bacterial Skin and Skin Structure Infection (ABSSSI) market. During the pandemic, healthcare resources were diverted towards managing COVID-19 patients, leading to delays in non-emergency procedures, elective surgeries, and routine medical visits. Furthermore, the economic repercussions of the pandemic, including job losses, reduced healthcare budgets, and supply chain disruptions, have created financial constraints for patients and healthcare systems, which hindered this market.

The hospital-acquired segment is expected to be the largest during the forecast period

The hospital-acquired segment is estimated to hold the largest share. It refers to infections that patients acquire during their hospital stay or healthcare facility visit. Hospital-acquired ABSSSI often involves a broader spectrum of bacteria compared to community-acquired infections. Additionally, healthcare providers must carefully consider the choice of antibiotics and may resort to broad-spectrum agents or combination therapy to effectively treat these infections, which significantly boosts this segment's expansion.

The gram staining segment is expected to have the highest CAGR during the forecast period

The gram staining segment is anticipated to have highest CAGR during the forecast period due to the fact that it is a diagnostic technique used to categorize bacteria based on their cell wall composition. Gram staining involves the application of crystal violet and iodine, which differentiates bacteria into two main groups: gram-positive and gram-negative. Moreover, advancements in Gram staining techniques, such as rapid automated systems and point-of-care testing devices, are driving growth within this segment.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a diverse healthcare landscape and varying patterns of infection prevalence across countries. The region's robust healthcare infrastructure and emphasis on evidence-based medicine drive demand for innovative treatments and diagnostic solutions for ABSSSI. Furthermore, collaborations between stakeholders drive innovation, clinical research, and the adoption of advanced diagnostic technologies, thereby driving this region's expansion.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to an increased focus on improving diagnostic capabilities, enhancing infection prevention measures, and developing novel therapeutics to address the rising incidence of ABSSSI. This region is home to some of the major players, such as Melinta Therapeutics, Inc., Melinta Therapeutics, Inc., and Pfizer, Inc. Therefore, it presents significant opportunities for companies to innovate, expand their product offerings, contribute to improving patient outcomes, and drive the region's growth.

Key players in the market

Some of the key players in the Acute Bacterial Skin & Skin Structure Infection Market include Paratek Pharmaceuticals, Inc., Merck & Co., Inc., Cumberland Pharmaceuticals Inc., Allergan, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Glenmark Pharmaceuticals Ltd, Endo Pharmaceuticals Inc., Nabriva Therapeutics PLC, Basilea Pharmaceutica Ltd, Melinta Therapeutics, Inc., Menarini Group and Sandoz Inc.

Key Developments:

In January 2024, Glenmark Pharmaceuticals Ltd. announced the launch of their alliance - Ichnos Glenmark Innovation - to accelerate new drug discovery in cancer treatment.

In December 2023, Pfizer Inc. announced topline data from the Phase 2b clinical trial investigating its oral Glucagon-like peptide-1 receptor agonist candidate, danuglipron, in adults with obesity and without type 2 diabetes.

In September 2023, Glenmark Pharmaceuticals Limited has entered into a definitive agreement with Nirma Limited to divest 75% stake in its subsidiary, Glenmark Life Sciences Limited ("GLS"), for an aggregate consideration, subject to closing adjustments.

Infection Types Covered:

  • Community-Acquired
  • Hospital-Acquired
  • Other Infection Types

Diagnostic Types Covered:

  • Clinical Diagnosis
  • Gram Staining
  • Blood Tests
  • Biomarker Assays
  • Molecular Diagnostics
  • Microbiological Cultures
  • Other Diagnostic Types

Treatments Covered:

  • Tedizolid
  • Delafloxacin
  • Daptomycin
  • Vancomycin
  • Tigecycline
  • Ceftaroline fosamil
  • Linezolid
  • Oritavancin
  • Other Treatments

Route of Administration Covered:

  • Parenteral
  • Topical
  • Oral

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Acute Bacterial Skin & Skin Structure Infection Market, By Infection Type

  • 5.1 Introduction
  • 5.2 Community-Acquired
  • 5.3 Hospital-Acquired
  • 5.4 Other Infection Types

6 Global Acute Bacterial Skin & Skin Structure Infection Market, By Diagnostic Type

  • 6.1 Introduction
  • 6.2 Clinical Diagnosis
  • 6.3 Gram Staining
  • 6.4 Blood Tests
  • 6.5 Biomarker Assays
  • 6.6 Molecular Diagnostics
  • 6.7 Microbiological Cultures
  • 6.8 Other Diagnostic Types

7 Global Acute Bacterial Skin & Skin Structure Infection Market, By Treatment

  • 7.1 Introduction
  • 7.2 Tedizolid
  • 7.3 Delafloxacin
  • 7.4 Daptomycin
  • 7.5 Vancomycin
  • 7.6 Tigecycline
  • 7.7 Ceftaroline fosamil
  • 7.8 Linezolid
  • 7.9 Oritavancin
  • 7.10 Other Treatments

8 Global Acute Bacterial Skin & Skin Structure Infection Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Parenteral
  • 8.3 Topical
  • 8.4 Oral

9 Global Acute Bacterial Skin & Skin Structure Infection Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Retail Pharmacies
  • 9.3 Hospital Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Other Distribution Channels

10 Global Acute Bacterial Skin & Skin Structure Infection Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Paratek Pharmaceuticals, Inc.
  • 12.2 Merck & Co., Inc.
  • 12.3 Cumberland Pharmaceuticals Inc.
  • 12.4 Allergan
  • 12.5 Pfizer Inc.
  • 12.6 Teva Pharmaceutical Industries Ltd.
  • 12.7 Melinta Therapeutics, Inc.
  • 12.8 Glenmark Pharmaceuticals Ltd
  • 12.9 Endo Pharmaceuticals Inc.
  • 12.10 Nabriva Therapeutics PLC
  • 12.11 Basilea Pharmaceutica Ltd
  • 12.12 Cipher Pharmaceuticals
  • 12.13 Menarini Group
  • 12.14 Sandoz Inc.

List of Tables

  • Table 1 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Infection Type (2021-2030) ($MN)
  • Table 3 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Community-Acquired (2021-2030) ($MN)
  • Table 4 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Hospital-Acquired (2021-2030) ($MN)
  • Table 5 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Infection Types (2021-2030) ($MN)
  • Table 6 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Diagnostic Type (2021-2030) ($MN)
  • Table 7 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Clinical Diagnosis (2021-2030) ($MN)
  • Table 8 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Gram Staining (2021-2030) ($MN)
  • Table 9 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 10 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Biomarker Assays (2021-2030) ($MN)
  • Table 10 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 11 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Microbiological Cultures (2021-2030) ($MN)
  • Table 12 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Diagnostic Types (2021-2030) ($MN)
  • Table 14 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 15 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Tedizolid (2021-2030) ($MN)
  • Table 16 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Delafloxacin (2021-2030) ($MN)
  • Table 17 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Daptomycin (2021-2030) ($MN)
  • Table 18 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Vancomycin (2021-2030) ($MN)
  • Table 19 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Tigecycline (2021-2030) ($MN)
  • Table 20 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Ceftaroline fosamil (2021-2030) ($MN)
  • Table 21 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Linezolid (2021-2030) ($MN)
  • Table 22 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Oritavancin (2021-2030) ($MN)
  • Table 23 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 24 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 25 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 26 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Topical (2021-2030) ($MN)
  • Table 27 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Oral (2021-2030) ($MN)
  • Table 28 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 29 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 30 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 31 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 32 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Table Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.